A novel peptide aldehyde with activity against human cytomegalovirus in two different in vivo models.
Novel peptide aldehydes (PAs) were identified as potent inhibitors of human cytomegalovirus (HCMV) in vitro. Although these compounds were highly effective against HCMV, they did not exhibit any activity against murine cytomegalovirus (MCMV). The purpose of this study was to test the antiviral activity of PA 8 as a representative of this novel class of inhibitors against HCMV in vivo. Because of the strict species specificity of HCMV we had to use two artificial animal models. In the first model, HCMV-infected human cells were entrapped into agarose plugs and transplanted into mice. In the second model, SCID mice were transplanted with human tissues that were subsequently infected with a clinical isolate of HCMV. In these two models the antiviral activity of PA 8 was clearly demonstrated, ganciclovir only being slightly superior in its in vivo antiviral activity.
Weber
O
O
Department of Antiinfective Research, Virology, Bayer Pharmaceutical Research Centre, Wuppertal, Germany. Olaf.Weber.OW@bayer-ag.de
Reefschläger
J
J
Rübsamen-Waigmann
H
H
Raddatz
S
S
Hesseling
M
M
Häbich
D
D
D000447:Aldehydes / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D003587:Cytomegalovirus / Q000187:drug effects*; D005260:Female; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D016513:Mice, SCID; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology*; D016339:Spectrometry, Mass, Fast Atom Bombardment
D000447:Aldehydes; D010455:Peptides